PMID- 24627347
OWN - NLM
STAT- MEDLINE
DCOM- 20150114
LR  - 20240130
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
VI  - 21
IP  - 3
DP  - 2014 Jun
TI  - Experience of low-dose aminophylline use to relieve minor adverse effects of 
      dipyridamole in patients undergoing stress myocardial perfusion imaging.
PG  - 563-9
LID - 10.1007/s12350-014-9883-7 [doi]
AB  - BACKGROUND: Intravenous administration of aminophylline is widely adopted to 
      reverse dipyridamole-related adverse effects (AEs) during stress myocardial 
      perfusion imaging (MPI). The study aimed to investigate the efficacy of 
      lower-dose aminophylline to relieve minor AEs. METHODS: 2,250 consecutive 
      patients undergoing dipyridamole-stressed MPI were enrolled. Information 
      concerning AE occurrence and dosages of aminophylline was collected to evaluate 
      the efficacy of lower-dose aminophylline. A logistic regression was used to 
      determine independent predictors of dipyridamole-related AE occurrence. RESULTS: 
      No severe AE was noted. Overall mild AE incidence was 37.0% (833/2,250 patients). 
      Initial low-dose (25 mg) aminophylline relieved symptoms in 98.8% of patients 
      with mild AEs (823/833 patients). An extra 25 mg aminophylline sufficed to 
      reverse all such AEs. Mean body mass index (BMI) differed significantly between 
      patients with and without any AE [25.6 vs 25.1 (P = .009)]. There was no 
      significant difference between two subgroups in mean age, male gender prevalence, 
      body height and weight, dipyridamole dose/BMI, or prevalence of significant 
      perfusion defect(s) on MPI. Multivariable logistic regression demonstrated BMI 
      remained the independent predictor of dipyridamole-related AE occurrence (odds 
      ratio 1.028, 95% confidence interval 1.007-1.049, P = .01). CONCLUSION: Low-dose 
      (<==50 mg, and usually 25 mg) aminophylline seems sufficient to relieve mild 
      dipyridamole-related AEs during stress MPI.
FAU - Lin, Li-Fan
AU  - Lin LF
AD  - PET center and Department of Nuclear Medicine, Tri-Service General Hospital & 
      National Defense Medical Center, 325, Cheng-Kung Road, Section 2, Taipei, 114, 
      Taiwan, ROC.
FAU - Cheng, Cheng-Yi
AU  - Cheng CY
FAU - Hou, Cheng-Han
AU  - Hou CH
FAU - Ku, Chih-Hung
AU  - Ku CH
FAU - Tseng, Neng-Chuan
AU  - Tseng NC
FAU - Shen, Daniel H Y
AU  - Shen DH
LA  - eng
PT  - Journal Article
DEP - 20140314
PL  - United States
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of 
      Nuclear Cardiology
JID - 9423534
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Thallium Radioisotopes)
RN  - 0 (Vasodilator Agents)
RN  - 27Y3KJK423 (Aminophylline)
RN  - 64ALC7F90C (Dipyridamole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminophylline/*administration & dosage
MH  - Cardiotonic Agents/administration & dosage
MH  - Comorbidity
MH  - Coronary Artery Disease/*diagnostic imaging/*epidemiology
MH  - *Dipyridamole/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Exercise Test/adverse effects/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Perfusion Imaging/adverse effects/*statistics & numerical data
MH  - Prevalence
MH  - Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thallium Radioisotopes
MH  - Tomography, Emission-Computed, Single-Photon/adverse effects/*statistics & 
      numerical data
MH  - Treatment Outcome
MH  - Vasodilator Agents/adverse effects
MH  - Young Adult
EDAT- 2014/03/15 06:00
MHDA- 2015/01/15 06:00
CRDT- 2014/03/15 06:00
PHST- 2013/05/16 00:00 [received]
PHST- 2014/02/25 00:00 [accepted]
PHST- 2014/03/15 06:00 [entrez]
PHST- 2014/03/15 06:00 [pubmed]
PHST- 2015/01/15 06:00 [medline]
AID - S1071-3581(23)07288-4 [pii]
AID - 10.1007/s12350-014-9883-7 [doi]
PST - ppublish
SO  - J Nucl Cardiol. 2014 Jun;21(3):563-9. doi: 10.1007/s12350-014-9883-7. Epub 2014 
      Mar 14.